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Background
The HSV-1 d106 mutant virus is a promising viral vector
because it allows robust expression of the foreign antigen,
induces a balanced cellular and humoral immune
response and is efficacious in HSV-immune animals. It
has deletions in immediate-early genes ICP4, ICP22,
ICP27 and ICP47 that render it absolutely replication-
deficient in normal cells, thus making it safe for use as a
vaccine vector. Recently, in a prime-boost regimen, d106
recombinants expressing SIV proteins have shown signifi-
cant protection in the SIVmac239 challenge model in rhe-
sus macaques (Kaur et al., 2007 and unpublished results).
Methods
Using homologous recombination we have engineered an
HSV-1 d106 recombinant vector that expresses a codon-
optimized envelope glycoprotein (env) of Clade A HIV-1.
Western blotting and immunofluorescence analysis indi-
cate that robust expression of env continues for as long as
48 hours post infection in infected cells in culture, and
that the env expression cassette is completely stable in the
vector for at least 8–10 passages of the recombinant virus
in culture. Viral yields of 250 pfu/cell are observed; thus,
production should be feasible. Quantitative real-time
PCR enumerates viral preparations as having particle: PFU
ratios of 10–80, documenting the high specific infectivity
of the preparations.
Results
These results support the development of d106-EnvA as a
lead vector for clinical trials and our studies strengthen the
potential of these recombinant vectors as promising clin-
ical products.
Conclusion
This work is part of an effort to generate a panel of repli-
cation-deficient HSV-1 vectors expressing HIV antigens
from various clades, which will allow a comparison of
other viral vaccine vectors and development of potential
combined vaccine regimens in the search for an effective
HIV vaccine.
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